Novo Nordisk, Denmark’s largest company and the Nordic region’s most valuable listed business, will from now on call itself simply Novo. In a statement from its Bagsværd headquarters on Monday 14 September the group unveiled a rebrand built around the line “Lasting Health Starts Now”, a single day-to-day name, a refreshed version of its century-old Apis bull logo and a new set of cultural principles it calls “The Novo Way”. Novo Nordisk A/S remains the legal name of the parent, and the company said a detailed account of its updated corporate strategy will follow at a Capital Markets Day in London on 21 September. For the Portugal ↔ Scandinavia corridor, the announcement matters less as a logo story than as the clearest signal yet of how the new management intends to run a company whose Portuguese affiliate and Portuguese suppliers sit inside the world’s most contested drug market.
The wording of the statement is the tell. Mike Doustdar, president and chief executive since August 2025, said that “healthcare must become more responsive, relevant and easier to fit into everyday life” and that “our brand and culture are strategically important and will enhance how we operate and compete, but the reason we exist will not change”. Tania Sabroe, executive vice-president for people, organisation and corporate affairs, described a company that needs to “move with focus and speed” in “a faster, more competitive and increasingly consumer-driven market”. Those are not the phrases of a company defending a monopoly. They are the phrases of one that, as NorthSouth HQ reported after the second-quarter results on 4 August, is guiding to a year of flat-to-shrinking sales at constant exchange rates — minus 6% to zero — while its US rival Eli Lilly takes share in obesity.
Four principles and a consumer market
“The Novo Way” is four principles: customer obsession (“we innovate with consumers and patients at the centre of everything we do”), competitiveness (“we raise our performance to create greater value for all our stakeholders”), clarity (“we create focus and speed through clear priorities, simple ways of working and decisive action”) and care and integrity (“we care for our people, show respect, and never compromise on patient safety and ethics”). The company says the framework builds on what has defined it for more than a century — breakthrough science, deep expertise, care for people and patient safety — while setting out “the behaviours and ways of working needed to innovate and lead” in a consumer-driven market. The reference to consumers is deliberate: the obesity franchise, and in particular the Wegovy tablet, is sold to people who choose a brand in a way that insulin patients never did.
The rebrand follows a year of restructuring under Doustdar, who took over from Lars Fruergaard Jørgensen and moved within weeks to cut around 9,000 positions worldwide. The statement now describes a workforce of “over 67,000 employees”. It also follows the second-quarter print in which adjusted operating profit rose 11% at constant exchange rates to DKK 33.4 billion on sales of DKK 78.5 billion, the outlook was raised from a deeper contraction, and the Wegovy pill passed 265,000 weekly US prescriptions. The group is controlled by the Novo Nordisk Foundation through Novo Holdings, which is one reason a name change of this kind can be executed without a shareholder fight: the foundation’s name, and the legal entity’s, are untouched.
What changes in Paço de Arcos, and what does not
Novo’s Portuguese presence runs through Novo Nordisk Comércio Produtos Farmacêuticos, Lda, the affiliate headquartered in Paço de Arcos, in the Oeiras municipality west of Lisbon, which handles regulatory affairs, market access, medical affairs and the commercialisation of the diabetes, obesity, haemophilia and growth-disorder portfolios in Portugal — Ozempic, Wegovy, Saxenda, Tresiba, NovoRapid and the rest — in dealings with Infarmed, the medicines regulator, and the National Health Service. Nothing in Monday’s statement changes that structure; local legal entities keep the Novo Nordisk name, as the parent does. What changes is the brand the affiliate presents to Portuguese doctors, pharmacists and, increasingly, to patients who ask for an obesity drug by name.
The more consequential Portuguese link is industrial. As NorthSouth HQ has documented, the Loures-headquartered contract manufacturer Hovione, founded in 1959, is one of the world’s leading specialists in spray drying and particle engineering, the processes that turn fragile peptides such as semaglutide into stable tablets, and that expertise places it in the supply chain of Novo’s oral franchise. A management that has just told the market it wants “focus and speed” and “decisive action” is a management that will revisit its manufacturing footprint, its outsourcing mix and its cost base at the Capital Markets Day. Suppliers get paid on volume, and the volume story — the tablet outgrowing the injection — is the part of the Novo narrative that is still working.
What to watch on 21 September
Three things are worth watching from Lisbon on 21 September. First, any statement on manufacturing capacity and external partners: Novo has spent the past three years buying and building fill-finish and API capacity, and a “clarity” agenda usually means fewer, larger commitments. Second, the commercial model for obesity outside the United States, where Portugal is a small but reimbursed diabetes market and a largely out-of-pocket obesity market; a consumer-facing brand called Novo is being built for exactly that kind of country. Third, the cost programme: the Portuguese affiliate is one of dozens of European sales organisations, and the 2025 job cuts were framed as a way to fund commercial investment in obesity and diabetes rather than to shrink it.
For the corridor the rebrand is a reminder of scale. Novo is one of the largest Nordic-owned healthcare operations in Portugal, a reference point for the country’s most sophisticated pharmaceutical exporter, and, through Novo Holdings, one of the largest pools of Danish capital looking for European investments. Danish pharma and medtech in Portugal — Novonesis, LEO Pharma, Lundbeck, Coloplast and others — are mapped in the Danish Companies in Portugal directory. Whether the new name sticks in Portuguese clinics will take years to judge; what the strategy behind it means for Paço de Arcos and Loures should be clearer within the week.